Study examines arrhythmias in ATTR-CM, a frequent complication
Arrhythmias appear to be a common complication in patients with ATTR-CM and may contribute to an increased risk of mortality.
Arrhythmias appear to be a common complication in patients with ATTR-CM and may contribute to an increased risk of mortality.
Abnormalities in the function of arteries and small blood vessels represent a key component of ATTR-CM pathology and a therapeutic target.
A recently published review summarized the advances in ATTR-CM screening, diagnosis and treatment and analyzed future perspectives.
Tafamidis can improve survival in octogenarian patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with ATTR-CM.
A new study reports that treatment with acoramidis decreases the rate of all-cause mortality and cardiovascular hospitalization in patients with ATTR-CM.
Gene silencing and antifibril therapy could stop disease progression and eliminate amyloid deposits in patients with ATTR-CM.
The barriers to treatment of ATTR-CM included lack of affordability, delayed diagnosis and underrepresented populations in clinical trials.
A case of transthyretin amyloid cardiomyopathy (ATTR-CM) presented with symptoms generally associated with a different heart condition.
The stroke volume index appears to have greater prognostic accuracy for mortality in ATTR-CM than traditional echocardiographic indexes.